Evidence map›Paper›PMID 26361060›Full record

Trial reportNeuropsychopharmacology : official publication of the American College of Neuropsychopharmacology2016

Randomized Placebo-Controlled Trial of Methylphenidate or Galantamine for Persistent Emotional and Cognitive Symptoms Associated with PTSD and/or Traumatic Brain Injury.

Thomas W McAllister, Ross Zafonte, Sonia Jain, Laura A Flashman, Mark S George, Gerald A Grant, Feng He, James B Lohr, Norberto Andaluz, Lanier Summerall and 3 more

3 registry-linked trialsOpen access · bronzeAbstract readMulticenter StudyRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to 3 registered trials, which are not on this map. Cited by 52 papers, 2 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
52citing papers in PubMed, 2 pooled it
6.5field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04885257 phase1 / phase2completednot on this mapstarted 2022, after this paper: background citation

A Randomized Placebo-controlled Trial of Methylphenidate in Veterans With a Diagnosis of Post Traumatic Stress Disorder and Recent Cerebral Stroke

TypeinterventionalSponsorVA Office of Research and DevelopmentRan2022 to 2025Enrolled20ConditionsPTSD, StrokeArmsMethylphenidate, Placebo
NCT05133804 phase2recruitingnot on this mapstarted 2022, after this paper: background citation

The Relation Between Attentional, Sensory and Emotional Dysregulation in Adults With Posttraumatic Stress Disorder: a Double-blind, Placebo-controlled Randomized Controlled Trial of the Combined Treatment With Reboxetine and Methylphenidate

TypeinterventionalSponsorUniversity of HaifaRan2022 to 2026Enrolled53ConditionsPosttraumatic Stress DisorderArmsMethylphenidate, Reboxetine, Placebo
NCT07771530 phase2recruitingnot on this mapstarted 2026, after this paper: background citation

Evaluating the Efficacies of an Innovative Pharmacological Treatment (Reboxetine Plus Ritalin) Versus Dog-Assisted Therapy in PTSD: A Randomized Controlled Trial

TypeinterventionalSponsorUniversity of HaifaRan2026 to 2028Enrolled160ConditionsPTSD, Posttraumatic Stress DisorderArmsmethylphenidate (Ritalin®), Reboxetine, Placebo, Dog-Assisted Therapy, Occupational Therapy
3 · Its place in the literature

Who cites it

52 citing papers in PubMed, 2 syntheses or guidelines pooled it, 101 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Trial
  4. Trial
  5. Trial
  6. Single doses of a highly selective inhibitor of phosphodiesterase 1 (lenrispodun) in healthy volunteers: a randomized pharmaco-fMRI clinical trial.Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology · 2022
    Trial
  7. Trial
  8. Trial
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Poorer Inhibitory Control Uniquely Contributes to Greater Functional Disability in Post-9/11 Veterans.Archives of clinical neuropsychology : the official journal of the National Academy of Neuropsychologists · 2023
    Article
  15. Interoception in Fear Learning and Posttraumatic Stress Disorder.Focus (American Psychiatric Publishing) · 2023
    Article
  16. Article
  17. Article
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 9 institutions in 1 country.

Thomas W McAllisterDepartment of Psychiatry, Indiana University School of Medicine, Indianapolis, IN, USA.
Ross ZafonteDepartment of Physical Medicine and Rehabilitation, Spaulding Rehabilitation Hospital, Massachusetts General Hospital, Brigham and Women's Hospital and Harvard Medical School, Boston MA, USA.
Sonia JainDepartment of Family Medicine and Public Health, Biostatistics Research Center, University of California, San Diego, CA, USA.
Laura A FlashmanDepartment of Psychiatry, Neuropsychology Program, Geisel School of Medicine at Dartmouth, Dartmouth-Hitchcock Medical Center, Lebanon, NH, USA.
Mark S GeorgeDepartment of Psychiatry, Medical University of South Carolina, Charleston, SC, USA.
Gerald A GrantDepartment of Neurosurgery, Stanford University/Lucile Packard Children's Hospital, Stanford CA, USA.
Feng HeDepartment of Family Medicine and Public Health, Biostatistics Research Center, University of California, San Diego, CA, USA.
James B LohrDepartment of Psychiatry, University of California, San Diego, CA, USA.
Norberto AndaluzDepartment of Neurosurgery, College of Medicine/Mayfield Clinic, Neuroscience Institute, University of Cincinnati, Cincinnati, OH, USA.
Lanier SummerallDepartment of Psychiatry, Ralph H. Johnson VA Medical Center, Charleston, SC, USA.
Martin P PaulusLaureate Institute for Brain Research, Tulsa, OK, USA.
Rema RamanDepartment of Family Medicine and Public Health, Biostatistics Research Center, University of California, San Diego, CA, USA.
Murray B SteinDepartment of Psychiatry and Department of Family Medicine and Public Health, University of California, San Diego, CA, USA.
University of California, San Diego · USDartmouth–Hitchcock Medical Center · USIndiana University – Purdue University Indianapolis · USLaureate Institute for Brain Research · USLucile Packard Children's Hospital · USMassachusetts General Hospital · USMedical University of South Carolina · USRalph H. Johnson VA Medical Center · USUniversity of Cincinnati Medical Center · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We report findings from a 12-week randomized double-blinded placebo-controlled trial of methylphenidate or galantamine to treat emotional and cognitive complaints in individuals (n=32) with a history of PTSD, TBI, or both conditions. In this small pilot study, methylphenidate treatment was associated with clinically meaningful and statistically significant improvement compared with placebo on the primary outcome, a measure of cognitive complaints (Ruff Neurobehavioral Inventory-Postmorbid Cognitive Scale), as well as on the secondary outcomes reflecting post-concussive (Rivermead Post Concussive Symptom Questionnaire) and post-traumatic stress symptoms (Posttraumatic Stress Disorder Checklist). Treatment was well tolerated. These results suggest the need for a larger RCT to replicate and confirm these findings. Design considerations for such a trial should include the need for multiple sites to facilitate adequate recruitment and extension of the treatment and follow-up periods.

Indexed as

AdultAffective SymptomsBrain Injuries, TraumaticCognition DisordersDouble-Blind MethodFemaleGalantamineHumansMaleMethylphenidateMiddle AgedNeuropsychological TestsPilot ProjectsStress Disorders, Post-TraumaticTreatment OutcomeGalantamineMethylphenidate

Identifiers

PMID26361060
PMCPMC4793116
OpenAlexW2228733445

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.